Intravenous racemic ketamine demonstrated superior clinical treatment response compared to intranasal esketamine (Spravato) in adults with major depressive disorder, according to real-world evidence presented as a peer-reviewed poster at the 2026 American Society of Clinical Psychopharmacology (ASCP) annual conference. The findings were highlighted by NRx Pharmaceuticals (Nasdaq: NRXP), whose pipeline includes ketamine-based therapeutic candidates, and were generated in collaboration with Osmind, Inc. and Prof. Samuel Wilkinson, MD, of the Yale University Department of Psychiatry.
The poster, titled "Real World Evidence of Clinical Treatment Response Following Intravenous Racemic Ketamine Versus Intranasal Esketamine in Adults with Major Depressive Disorder," was co-authored by Robert Dougherty, Emily Shih, Jamie Lo, and Jimmy Qian of Osmind — a data and analytics platform serving ketamine and psychedelic-assisted therapy clinics — alongside Wilkinson's Yale group. Unlike placebo-controlled efficacy trials, real-world evidence studies capture outcomes across heterogeneous patient populations and variable dosing protocols, making the data particularly relevant for clinical operators and formulators tracking how delivery route affects bioavailability and therapeutic response at the clinical endpoint level.
The mechanistic distinction between the two modalities is significant. IV racemic ketamine delivers a 50/50 mixture of R- and S-enantiomers directly into systemic circulation, achieving rapid and predictable plasma concentrations. Intranasal esketamine (the S-enantiomer, marketed as Spravato by Janssen) carries FDA approval for treatment-resistant depression but relies on transmucosal absorption, which introduces bioavailability variability. Researchers and clinicians in the psychobiotics and neuroactive compound space have long debated whether the full racemic profile confers additive or synergistic receptor activity beyond the S-enantiomer alone — a question this dataset moves closer to answering under real-world conditions.
For the functional foods and nutraceutical industry, the clinical trajectory of ketamine-adjacent mental health interventions sets a precedent for evidence standards in the broader mood and cognitive support category. As brands developing adaptogen and nootropic finished formulations compete for share in a mental wellness market projected to expand significantly through the decade, the bar for peer-reviewed, real-world clinical data is rising. Structure-function claims tied to stress, mood, and cognitive performance increasingly face scrutiny from both the FDA and sophisticated retail buyers demanding substantiation beyond preclinical endpoints.
NRx Pharmaceuticals has not disclosed a commercial timeline for its ketamine therapeutic candidate, but the company's decision to amplify Osmind's ASCP presentation signals continued investment in building a clinical evidence base. For operators and co-manufacturing partners watching the neuroactive therapeutics corridor, the real-world data gap between IV and intranasal delivery routes may inform protocol standardization and, downstream, ingredient selection discussions for ingestible mental wellness formats.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.